Physician profile
Michael Zeidman
NPI 1508108952
$909.16
in general payments reported to CMS, 2019-2025
8 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.74 · 2021: $163 · 2022: $16.29 · 2023: $127 · 2024: $280 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $377.81 | 2023-2025 | Localizer, Trunode, Trident Specimen Radiography System |
| Tactile Systems Technology INC | $224.75 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Coopersurgical, INC. | $96.44 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.74 | 2019 | |
| Menarini Silicon Biosystems, INC. | $50.03 | 2025 | |
| Merck Sharp & Dohme LLC | $25.56 | 2025 | Keytruda, Welireg |
| Stryker Corporation | $21.67 | 2025 | Molli, Spy-Phi System |
| Elucent Medical | $21.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zeidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.